Natural Capsules Subsidiary Allots 9.46 Lakh Rights Shares Worth ₹94.6 Lakh
Natural Biogenex Private Limited, a subsidiary of Natural Capsules Limited, has approved the allotment of 9,46,305 equity shares. This allotment, part of a Rights Issue approved on July 10, 2026, is valued at ₹94.63 Lakh.
The allotment is a routine corporate action for a subsidiary and the amount involved is relatively small for the parent company.
The announcement details a routine share allotment by a subsidiary as part of an approved rights issue. There are no significant positive or negative financial implications disclosed.
Natural Capsules Limited has announced the allotment of equity shares by its material unlisted subsidiary, Natural Biogenex Private Limited. The decision was made during the subsidiary's Board Meeting held on July 31, 2026.
This allotment pertains to the Right Issue that was previously approved by the Board on July 10, 2026. A total of 9,46,305 Equity Shares, each with a face value of ₹10, have been allotted for cash at par.
The aggregate value of this allotment amounts to ₹94,63,050 (Rupees Ninety-Four Lakh Sixty-Three Thousand and Fifty only).
What to do with a filing like this
Natural Capsules Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natural Capsules Limited. Read the original for the full detail.